0001144204-11-000365.txt : 20110331 0001144204-11-000365.hdr.sgml : 20110331 20110104125653 ACCESSION NUMBER: 0001144204-11-000365 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20110104 FILER: COMPANY DATA: COMPANY CONFORMED NAME: XTL BIOPHARMACEUTICALS LTD CENTRAL INDEX KEY: 0001023549 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: XTL BIOPHARMACEUTICALS LTD STREET 2: C/O ALSTON & BIRD LLP, 90 PARK AVENUE CITY: NEW YORK STATE: NY ZIP: 10016 BUSINESS PHONE: 972 9 955 7080 MAIL ADDRESS: STREET 1: 85 MEDINAT HAYEHUDIM ST. STREET 2: PITUACH, PO BOX 4033 CITY: HERZLIYA STATE: L3 ZIP: 46140 CORRESP 1 filename1.htm Unassociated Document
 

 
January 4, 2011

Securities and Exchange Commission
100 F Street N.E.
Washington, D.C. 20549
Attn: 
Jeffrey Riedler, Assistant Director
John Krug, Senior Counsel

Via: 
EDGAR Submission

Re: 
XTL Biopharmaceuticals Ltd.
Form 20-F filed June 30, 2010
File No. 000-51310

Ladies and Gentlemen:

Today, XTL Biopharmaceuticals Ltd. (the “Company”) received by United States Postal Service a letter from the Securities and Exchange Commission (the “Commission”), dated December 6, 2010, which requests comments on the Company’s Form 20-F filed June 30, 2010.

Pursuant to a telephone conversation held today between myself and Mr. Jeffrey Riedler, the Company and the Commission have agreed that the date of response to the above-referenced letter will be delayed until January 18, 2011 due to the late receipt of the letter.

Thank you for your assistance.
 
XTL Biopharmaceuticals Ltd.        
           
           
By:
/s/ David Grossman
   
 
 
 
David Grossman
   
 
 
 
Chief Executive Officer
   
 
 
 

XTL Biopharmaceuticals Ltd. 85 Medinat Hayehudim St., Herzliya Pituach 46766, Israel Tel: +972-9-955-7080 Fax: +972-9-951-9727

 
GRAPHIC 2 logo.jpg GRAPHIC begin 644 logo.jpg M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$! M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$" M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W^BL#QCXA MNO"_AZ75K;31?K`P\Z,S^450\%@=K9P<<</?B-9>"$MX3:M>W\XWI;B3RP$S@LS8..>!PJ::MD]PQ2*>.;YSTZ5@^`]"O]>\6Z>MC`[QVUS%-/*%)6)0V[+'MG:0/7 M\#77'#T_97EN.:A\>H+74KFWLM!%U;12,D=Q]MV>:H.-P7 MRS@'J.>F*Z7P3\1KOQBNH3C0!9V=E$6:;[7YFZ3J$`V#MDY[<>MWY!]8I]SVRBO$_ M^&@6_P"A7'_@P_\`M5'_``T"W_0KC_P8?_:J/JM7M^0?6*?<]LHJAHFHG6-! MT[4S%Y/VRVBN/+W;MF]`V,\9QG&<"K]<[5M#8***XJ/Q\TGB@Z-_9@'^EM;> M=Y_HQ7=C;[=,UI3I3J7Y5L8UL13HV]H[7T1VM%%%9FP445SOBOQ0?#,5LXLQ M<^>S+CS=FW`'L<]:N$)5)*,=V9U:L*4'.;LD=%16+X9UX^(M+-Z;;[/B5H]F M_=T`YS@>M;5*<7"3C+=#IU(U(*<=F%%%%26%%%%`#)8HYXGBF19(W4JZ.,A@ M>"".XKY7^(/A%_!_B>6T0'[#/F:T;)/R9^Z3ZJ>/I@]Z^JZY+XA^$5\7^&)+ M6)$^WPGS;1V.,/W7..`1Q^7I71AZOLY:[,QKTN>.FYY/\&/%BZ5KDN@WDG^A MZB1Y.>0DP_'@,.._(7WKMOBYXEMO#?A8:%IR1Q7.I!@5A^01Q9^=L#NQ./?+ M'M@_/@,MO,"#)#/$V01E'C8'\P01]016AX@UZ]\2ZQ+JFH%#<2*JG8,*`H`X M'Z_C7;*@I55/H<<:[C3<.I7TS3+S6=2@T[3X3-=3MLC0>OJ?0#J37U=H7AFT M\/>%UT2R+",1LK2-U=V'S.?J>U<#\&?!!TVP_P"$DU"(?:KM!]D!.=D)`.[& M."W_`*#CU->M5RXJMS2Y5LCIPU+EC=[L\''P"U3'.NV>?^N#?XUG:_\`!K4- M`T"]U:76+:9+6,R&-86!8#MG-?1-A\I5ZEI/P2U'5M&L=236K6-+NWCG5&A8E0ZAL$Y]Z\M[5]<^#/^1%\/_P#8 M-MO_`$4M=6*J2@DXLYL-3C-OF1XEK_P9U#0=!O=5DUBUFCM8C*T:PL"V.P.: M\SKZN^(O_).]>_Z]'KY1IX6I*<6Y"Q-.,)+E/KCP3_R(GA[_`+!EM_Z*6MVL M+P3_`,B)X>_[!EM_Z*6MVO,E\3/1CL(>AKQJV_Y*)37 MD>G^/[F\F#&.'49'8*,D@.>E>AEROSKR/&SEJ/LF_P"8]NHKQ^:'Q1XXWW21 M,UHK?)'O"1@CT!/)]_>J-QX:\1>'D&HF&2#R^LL$H)09[[3TZ5*P,?AE42EV M*EFL_CC1;AW_`%M8]NK)UOP]I_B!85OQ(1"25V/MZXSG\JY_P3XR.KE=-U#_ M`(_0I*2@<2@=<^C?SJ'XEWMU90:SX7S5!$MW*=S#MZFH)M/\`$?@J9;D, MUNCMM\R)]T;D=,CZ9QD9K=8*#?+&HN;L*(_ M$6GGS`J7L(`G11@>S#V/Z5T5<52$J]*$'.2BBI245=GC'Q3FTN;X@:@=+7`4A M;D@_*TXX?`QQZ'KR#7)V,MO!?V\UY;?:K9)%:6#>5\Q0>5R.1D4EE9W&H7MO M96D1EN)W6*)!_$Q.`/\`Z];'B_PM=>$-=;3+IQ+^[62.8+@2`CD@>Q!'X5[, M5&*4+GE.\FYV/JW3=0MM5TRVU"S??;W$:R1M[$9Y]#[5:KP7X+^-!87Q\,WK M8M[IR]JY8`1R8Y4^S=O<>_'O5>15ING+E/3I5%.-PKE_B/\`\DZUW_KU;^E= M17+_`!'_`.2=:[_UZM_2E3^->I4_A9\I=J^N?!G_`"(OA_\`[!MM_P"BEKY& M[5]<^#/^1%\/_P#8-MO_`$4M=V-^%'%@]V5/B+_R3O7O^O1Z^4:^KOB+_P`D M[U[_`*]'KY1IX+X&&+^)'UQX)_Y$3P]_V#+;_P!%+6[6%X)_Y$3P]_V#+;_T M4M;M>?+XF=T=A#T->#ZQ";CQ;J$"G#27\B`^A,A%>\'H:\4Q$?B-)YV/+_M5 M]V?^NAKT,N=G-^1XF=QYHTT^Y[-:6T5G9PVT*!(XD"*H[`<5)(BR1LCJ&5@0 M01P0:=0>E>:VWJ>VDDK'AD@;0/&CB%3$MK>$(&_N;N,^Q4_K77_%(@VFED=- M\F/R6N3\6,FH>--02,DAYQ#^(`0_J#75?$]=ECI*?W2X_1:]R6M:C)[M?H?* M0]W#8F"V37YEGP5=BP\!75V<_N7F?@9Z**Y/P5IW]M>+(C<8D2(-.FT[H^E: M35F>)^&WGT;QQ;0YPZW!M9!Z@G:<_C@_4"O;*\2E`N/B$XB(8/J9VD'@_O*] MMKTS"&VMT,DCD$X`]AR?I7RAXM\2 MW/BSQ%)O^640/RKCIGN?F0:=;ZNNGVRN7G4V M_F&4C&T9W#`')]^/2O/#^S]<$''B://_`%XG_P".5CAI4J?O2>IZ.(A4GI%: M"?!'PAYTTOBB\13'&3#9J>N[^-_P^Z/JW3`KMOBKX1'B?PLT\$;-J.GAI;<+ MDE@<;TQGG(4>^0,5V.F:=:Z1IMOI]E$(K:W01QH/0?U/4GN:M&L95I.I[1&L M:25/D9\61R/$Z2Q2/'(A#(Z,0RD="".A]Z^J/A]XO3QAX:CNG*+?0_NKN-<# M#_W@.P;J/Q':N-U_X'1ZKKUYJ%EK2V<-S(9?LYM=^QCRV#O'&F5 MR_Q'_P"2=:[_`->K?TKJ*RO$VCMX@\-W^DK.(#=Q&,2E-VW/?&1G\ZXH.TDV M=)-/T.T MEDGG1IE'RP*079NPQVZC\*Y#5_AB\ER\VDW<2(S9$$X("#OAADGGMC\:JV?P MNU!Y(S"*]G[*\N]]/4R_"6GS^( M?%PO)E!C24W,[;?E+9R%].3^F:Z+XJ?\>VF?[\G\EKL](T6RT2R6VLX@@X+O M_$[8QDGUK,\6>%V\31VJ+=BW\AF.3'OSD#W'I3^M1GB8S>D43_9\Z>!G2CK. M6K^]&;\/8DG\(/"X)5YI5./0@5P:?:?!OBT>8N][23L.)$(ZCZJ?S^E>K^&= M!;P]I?V)K@3_`+UGWA-O4#C&3Z4[7O#6G^(8`MW&5F08CG3AU_Q'M2ABH1K3 MOK&0ZN`J3PU/ETJ0M8LZ;K6GZM`DMG=1R;EW;-PW+]1U%9/B?Q;9:+I[B&9) MKV0%8XT8':?5O0"N1N/A=J:2+]DO[25<'+2[HR/P`;-6-.^%TOF*VIW\87)W M1VP))';YB!C\J%2PL7S.=UVL$L1F$X^S5*S[WT]3,\`:+)J>NC4)@QM[1MY8 M@_/)V&?;J?P]:]>JO8V-MIUG':VD2Q0QC"JO^>OO5BN?$UW7J